

University of Groningen

Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations

IMPACT Study Steering Comm; IMPACT Collaborators

Published in:
BJU International

DOI:
[10.1111/bju.14412](https://doi.org/10.1111/bju.14412)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2019

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
IMPACT Study Steering Comm, & IMPACT Collaborators (2019). Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations. *BJU International*, 123(2), 284-292. <https://doi.org/10.1111/bju.14412>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Psychosocial impact of undergoing prostate cancer screening for men with *BRCA1* or *BRCA2* mutations

Elizabeth K. Bancroft*[†] , Sibel Saya*[†], Elizabeth C. Page*[†], Kathryn Myhill*[†], Sarah Thomas*[†], Jennifer Pope*[†], Anthony Chamberlain*[†], Rachel Hart[‡], Wayne Glover[‡], Jackie Cook[§], Derek J. Rosario[¶], Brian T. Helfand*^{*}, Christina Hutten Selkirk*^{**}, Rosemarie Davidson^{††}, Mark Longmuir^{††}, Diana M. Eccles^{‡‡§§}, Neus Gadea^{¶¶}, Carole Brewer*^{**}, Julian Barwell^{††††‡‡}, Monica Salinas^{§§§}, Lynn Greenhalgh^{¶¶¶}, Marc Tischkowitz*^{***}, Alex Henderson^{††††}, David Gareth Evans^{‡‡‡‡}, Sandra S. Buys^{§§§§}, IMPACT Study Steering Committee¹, IMPACT Collaborators¹, Rosalind A. Eeles*[†] and Neil K. Aaronson^{¶¶¶¶}

*Oncogenetics Team, Royal Marsden NHS Foundation Trust, [†]Oncogenetics Team, Institute of Cancer Research, London, [‡]Clinical Genetics Unit, Birmingham Women's Hospital, Birmingham, [§]Sheffield Clinical Genetics Service, Sheffield Children's Hospital, [¶]Department of Urology, Royal Hallamshire Hospital, Sheffield, UK, ^{**}John and Carol Walter Center for Urological Health, NorthShore University HealthSystem, Evanston, IL, USA, ^{††}Clinical Genetics Department, Queen Elizabeth University Hospital, Glasgow, ^{‡‡}Wessex Clinical Genetics Service, Princess Anne Hospital, ^{§§§}Faculty of Medicine, University of Southampton, University Hospital Southampton NHS Foundation Trust, Southampton, UK, ^{¶¶}High Risk and Cancer Prevention Clinic, Vall d'Hebron University Hospital, Barcelona, Spain, ^{***}Clinical Genetics Department, Royal Devon and Exeter Hospital, Exeter, ^{†††}Department of Genetics, University of Leicester, ^{‡‡‡}Clinical Genetics, University Hospitals Leicester, Leicester, UK, ^{§§§§}Hereditary Cancer Programme, Catalan Institute of Oncology (ICO-IDIBELL, CIBERONC), L'Hospitalet de Llobregat, Barcelona, Spain, ^{¶¶¶¶}Cheshire and Mersey Clinical Genetics Service, Liverpool Women's Hospital, Liverpool, ^{*****}Academic Department of Medical Genetics, University of Cambridge, Cambridge, ^{†††††}Northern Genetics Service, Newcastle upon Tyne Hospitals, Newcastle, ^{‡‡‡‡}Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK, ^{§§§§§}Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT, USA, and ^{¶¶¶¶¶}Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands

E.K.B. and S.S. are joint first authors.

¹Full listing supplied in Appendix S1.

Objectives

To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi-national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic germline mutation in the *BRCA1* or *BRCA2* genes.

Participants and Methods

Men enrolled in the IMPACT study were invited to complete a questionnaire at collaborating sites prior to each annual screening visit. The questionnaire included sociodemographic characteristics and the following measures: the Hospital Anxiety and Depression Scale (HADS), Impact of Event Scale (IES), 36-item short-form health survey (SF-36), Memorial Anxiety Scale for Prostate Cancer, Cancer Worry Scale-Revised, risk perception and knowledge. The results of the baseline questionnaire are presented.

Results

A total of 432 men completed questionnaires: 98 and 160 had mutations in *BRCA1* and *BRCA2* genes, respectively, and 174 were controls (familial mutation negative). Participants' perception of PCa risk was influenced by genetic status. Knowledge levels were high and unrelated to genetic status. Mean scores for the HADS and SF-36 were within reported general population norms and mean IES scores were within normal range. IES mean intrusion and avoidance scores were significantly higher in *BRCA1/BRCA2* carriers than in controls and were higher in men with increased PCa risk perception. At the multivariate level, risk perception contributed more significantly to variance in IES scores than genetic status.

Conclusion

This is the first study to report the psychosocial profile of men with *BRCA1/BRCA2* mutations undergoing PCa screening. No clinically concerning levels of general or cancer-specific distress or poor quality of life were detected in the cohort as a whole. A

small subset of participants reported higher levels of distress, suggesting the need for healthcare professionals offering PCa screening to identify these risk factors and offer additional information and support to men seeking PCa screening.

Keywords

#pcsm, #ProstateCancer, *BRCA1*, *BRCA2*, psychosocial, quality of life

Introduction

Prostate cancer (PCa) is the most common non-melanoma tumour in men worldwide, with an estimated 1.1 million men diagnosed with PCa in 2012 [1]. Men with germline *BRCA1* or *BRCA2* gene mutations are known to be at an increased risk of PCa. This risk is estimated to be 1.8–3.75-fold and 2.5–8.6-fold increased by the age of 65 years for *BRCA1* and *BRCA2* mutation carriers, respectively [2,3]. Whilst there is some debate about whether there is a true increased risk of PCa for *BRCA1* mutation carriers, there is solid evidence that *BRCA2* mutation carriers present at a younger age and with aggressive disease [4,5]; therefore, prostate screening and early detection could have an important role in reducing the disease burden, particularly among *BRCA2* mutation carriers [6].

There is controversy about PCa screening using PSA testing in the general population and the benefits and harms of screening have been widely debated [7]. The US Prevention Services Task Force currently recommends shared decision-making for screening healthy men aged 55–69 years [7,8]. Additionally, PCa treatments have significant long-term side effects that can have an impact on masculine identity, physical and psychosocial symptoms and health-related quality of life (HRQoL). Research is therefore needed to identify targeted screening tools that can improve the benefit to harm ratio for PCa screening.

The limited number of studies evaluating men with a family history of PCa have generally supported the use of screening in this population [9–12]. To our knowledge, no studies, to date, have prospectively evaluated a PCa screening programme for *BRCA1/2* mutation carriers. The IMPACT study (Identification of Men with a genetic predisposition to Prostate Cancer: Targeted Screening in men at higher genetic risk and controls) is an international, multicentre study evaluating the role of targeted PSA screening in men with *BRCA1/2* mutations [6].

Evidence supports the theory that genetic testing for *BRCA1* and *BRCA2* mutations does not have a significant long-term psychological impact on most people tested [13,14]. Studies in men undergoing PCa screening suggest that a minority experience some anxiety, usually while waiting for results [15–17]. Risk factors for anxiety include having a family history of PCa, symptoms or abnormal genetic test results

[15–17]. As *BRCA1/BRCA2* mutations confer an increased disease risk and psychological distress [18], it is possible that higher levels of anxiety may exist in people with this mutation; however, risk perception has been shown not to reflect true risk in both men with and without a family history of PCa. It has also been reported that cancer worry is high in men with a family history of PCa, with the number of relatives dying from the disease predicting level of worry [18]; however, a low level of PCa worry has also been reported in men with a close relative with PCa [19].

Many issues arise when counselling men with *BRCA1/BRCA2* mutations, and many factors affect the way in which men react to and use information about their genetic status and risk of developing cancer [20–22]. So far, there have been few investigations either into the HRQoL impact for a man with a *BRCA1/BRCA2* mutation living with an increased risk of PCa, or in those men who have gone on to develop PCa [23]. Several studies have confirmed the feasibility of collecting HRQoL and psychosocial data as part of large PCa screening trials [16,24–28].

In the present study, we report the baseline results of a longitudinal HRQoL investigation carried out as part of the IMPACT study. The specific aims of the study were to evaluate the baseline psychosocial profile of men in the IMPACT study and to identify possible predictors of high levels of psychological distress or poor HRQoL.

Participants and Methods

Study Sample and Procedures

The IMPACT study recruited men from families with *BRCA1* or *BRCA2* mutations, with or without the familial mutation, to a programme of annual PCa screening via PSA testing, for a minimum of 5 years. The IMPACT study opened in 2005 and screening will end in 2019. The full design and methods of the IMPACT study have previously been reported [6]. The IMPACT study protocol was approved by the West Midlands Research and Ethics Committee in the UK (reference 05/MRE07/25) and subsequently by each participating institution's local ethics committee.

All men eligible for IMPACT were also eligible for the HRQoL study. Men were eligible for participation if they tested either positive, negative or were at 50% risk of

inheriting the familial *BRCA1/BRCA2* mutation and were aged 40–69 years. Men who tested negative for their familial mutation constituted the control group. Men were excluded if they were known to have PCa at enrolment or if they had another cancer with a prognosis of <5 years survival.

The HRQoL study was added to the IMPACT study protocol in 2009. All sites were invited to participate in this sub-study. Men enrolled in the IMPACT study at participating sites were approached by letter prior to their next scheduled study appointment inviting them to take part in the HRQoL study. The HRQoL study involves completing a set of questionnaires annually for 5 years, with each assessment taking place prior to the annual PSA test. Men were sent the questionnaires ~4 weeks before their appointment and asked to post it back or bring the completed questionnaire to their appointment. Men were split into two cohorts: (i) a prospective arm, which included men who joined the HRQoL study before their first PSA screening within the IMPACT study; and (ii) a truncated prospective arm, which included men already enrolled in the IMPACT study before joining the HRQoL study. The total target sample was a minimum of 300 men in each arm. In the present analysis, we report the results of the baseline questionnaires in the prospective (not truncated) cohort.

Study Measures

Psychological Distress

Distress was assessed using the Hospital Anxiety and Depression Scale (HADS), the Impact of Event Scale (IES), the Cancer Worry Scale-Revised (CWS-R), and the Memorial Anxiety Scale for Prostate Cancer (MAX-PC). The HADS contains two subscales of seven items that measure the presence and severity of general anxiety and depression [29]. Each subscale generates a score ranging from 0 to 21, and a score of >10 indicates clinically relevant levels of anxiety or depression.

The IES is a 15-item scale measuring PCa-specific distress through the frequency of intrusive or avoidant thoughts about PCa [30]. Total scores on the intrusion and avoidance scales range from 0–35 to 0–40, respectively. A higher score indicates more frequent intrusive/avoidant thoughts about risk of cancer; a score of >8.5 indicates clinically relevant levels of distress.

The CWS-R is a six-item scale that measures worry about the risk of developing cancer and the frequency and impact of that worry on mood and daily functioning [31,32]. The CWS-R uses a score of 1 (no worry) to 4 (maximum worry), giving a summative score between 4 and 24. A high score indicates greater worry, but no clinical thresholds for the scores are available.

The MAX-PC includes three scales assessing PCa anxiety, PSA anxiety, and fear of recurrence. In the present study, we

used the PCa anxiety (11 items) and PSA anxiety (3 items) scales [33]. The PCa anxiety scale is scored from 0 to 33 and the PSA anxiety scale from 0 to 9, with a higher score indicating higher anxiety levels.

Health-Related Quality of Life

We assessed HRQoL using the 36-item short-form health survey (SF-36) version 2.0 [34,35]. This questionnaire consists of eight subscales: physical functioning; social functioning; role limitations attributable to physical problems; role limitations attributable to emotional problems; mental health; vitality; pain; and general health. Summary scores are calculated for two broad areas of subjective well-being: physical health and mental health. All scales are linearly converted to a 0–100 scale, with a higher score representing better functioning.

Risk Perception

Men were asked to rate their perceived risk of PCa compared with the average man's risk: lower; the same; slightly increased; moderately increased; or strongly increased [36].

Knowledge

We developed a 'knowledge' questionnaire based on a measure developed by Lerman *et al.* [37] and Wonderlick and Fine [38]. The nine true/false items (Fig. 1) assessed knowledge of inheritance of *BRCA1/BRCA2*, the effect of having an altered gene, and risk of PCa. Knowledge scores were created by taking the sum of the correct responses to the nine items.

The internal consistency reliability, as assessed by Cronbach's coefficient α , was high for all measures used, ranging from 0.79 for the SF-36 General Health scale to 0.96 for the SF-36 Role Physical scale. Fourteen of the 15 scales had an α coefficient >0.80.

Statistical Analysis

The dataset contained a small amount of missing data. For all scales, except the SF-36, if $\geq 75\%$ of a subscale was complete then a total score (corrected for the total number of questions) was calculated. If <75% was completed, data were excluded. For the SF-36 score, scales were excluded when there was <50% of a sub-scale completed, as per the recommendation of the scale's authors [39]. Ten percent of the data entered were double-checked for coding accuracy and completeness, and no errors were identified.

The SPSS 22.0 statistical computer package (SPSS Inc., Chicago, IL, USA) was used to manage and analyse the data. Scores for each questionnaire were calculated in accordance with each scale's scoring system. Descriptive statistics,

Fig. 1 Knowledge questionnaire.

	True	False
1. One-half of all cases of prostate cancer are caused by BRCA1/2 mutations.		
2. A father can pass BRCA1/2 mutations to his daughters.		
3. About one in 10 men have an altered BRCA1/2 gene.		
4. There are many different genes that cause prostate cancer.		
5. A man with an altered BRCA1/2 gene has a 50% chance of passing it to each of his children.		
6. Even if a man does not have an altered BRCA1/2 gene, his children can get it from their grandmother / grandfather (his parents) i.e. the gene alteration can skip generations.		
7. If a man carries a gene mutation associated with prostate cancer, he will always develop prostate cancer at some point during his lifetime.		
8. If a man does not carry a gene mutation associated with prostate cancer, he will not develop prostate cancer.		
9. Every man who has been diagnosed with prostate cancer carries a gene mutation associated with prostate cancer.		

including means and standard deviations, were used to summarize the sample characteristics and questionnaire data.

All psychometric scales (HADS, IES, SF-36, MAX-PC and CWS-R) were skewed towards better scores. Neither log nor square-root transformations of these scales produced normal distributions, but given the large sample size within each genetic cohort, parametric tests were used. To minimize the potential effect of multiple testing on the Type I error rate, a *P* value of <0.01 was regarded as statistically significant.

Univariate analysis was used to examine if there were any measurable differences at baseline between *BRCA1* mutation carriers, *BRCA2* mutation carriers and controls on the dependent variables risk perception, HRQoL (SF-36), the psychological measures (HADS, IES, MAX-PC) or knowledge. As UK participants made up the largest proportion of participants, a UK dataset was used as a normative comparator for HRQoL, by randomly selecting individuals matched to our sample on age. Means were then compared using a paired Student's *t*-test [34]. Only those aged up to 64 years were recruited to this large population-based study therefore we limited the analysis to men aged 40–64 years from the IMPACT cohort for the comparison.

The impact of other variables on psychosocial outcomes was also explored. Independent variables included demographics (age, employment status and education), prior PSA screening, family history of PCa, time since genetic testing, and comorbidities coded from clinical interview into a Charlson

Comorbidity Index score [40]. Knowledge of genetics and PCa and risk perception were also included as independent variables, to examine their impact on psychosocial outcomes.

The associations were investigated initially with ANOVA, Student's *t*-tests, chi-squared tests and Pearson's correlations, as appropriate. For categorical independent variables, strength of association was calculated with Cohen's *d* for any significant relationship. Subsequently, multivariate linear regression analyses were performed employing all independent variables found to be associated significantly at the univariate level with a psychosocial outcome.

Results

Sample Characteristics and Response Rate

Of the 65 centres participating in the IMPACT study, 23 agreed to take part in the HRQoL sub-study, including all 19 UK centres, two in Spain and two in the USA. The main reasons for electing not to participate as a centre were financial; there was no specific funding to support this sub-study at collaborating sites outside of the UK. A total of 780 men enrolled in the HRQoL study, of whom 476 enrolled prior to their first screening visit (prospective cohort, reported in the present paper). This corresponds to 26% of the participants in the IMPACT study taking part in this sub-study. Those who returned their questionnaire >1 month

after their initial screening visit or had not returned the study consent form were excluded ($n = 35$), as were nine men who were untested for their familial mutation, remaining at 50% risk. The data presented are therefore from 432 men, 351 of whom were recruited in the UK, 50 from the USA and 31 from Spain. No significant differences in responses were observed between nationalities.

Uptake into the HRQoL sub-study was 85–100% at participating sites. There was no significant difference in the participants' sociodemographics (employment status or education) between the men in this sub-study and those in the parent IMPACT study.

In all, 98 men (22.7%) carried a mutation in the *BRCA1* gene, 160 (37.0%) carried a mutation in the *BRCA2* gene and 174 (40.3%) were controls. The median time from undergoing genetic testing to joining the IMPACT study was 7.2 months (range 0 months–15.4 years); 47.4% of men joined within 6 months of testing, and 39.6% of men had had at least one PSA measurement before they joined the IMPACT study.

The sociodemographic characteristics and family cancer history of the cohort are shown in Table 1. The mean age of the men when they completed the baseline questionnaire was 53.1 years. The majority were white (98.9%) and in higher managerial or professional occupations (55.3%), and employment and education levels were similar to the UK general population, with 4.4% unemployed and 37.7% having college degrees or postgraduate qualifications [41,42].

Risk Perception and Knowledge

Participants' perception of their lifetime risk of PCa was influenced significantly by their carrier status ($P < 0.001$;

Table 2). *BRCA2* mutation carriers were more likely to rate their risk of PCa as moderately or strongly increased compared with the general population than the control group.

Knowledge scores were not affected by the genetic status of the participant, time since genetic testing or education level. Family history of PCa, education level, time since genetic testing and age were not significantly associated with any of the outcome variables.

SF-36 Questionnaire

Overall physical functioning SF-36 scores did not differ significantly from the normative sample (IMPACT sample aged 40–64 years mean score: 48.1; matched normative sample mean score: 47.5; $P = 0.52$). The overall mental functioning SF-36 score was significantly better in the study cohort compared with the normative sample, but the effect size was small and both mean values were close to the standardized mean of 50 (IMPACT sample aged 40–64 years mean score: 52.0; matched normative sample mean score: 49.8; $P = 0.008$, Cohen's $d = 0.21$). Means also did not differ significantly across genetic groups.

HADS Questionnaire

The overall mean anxiety and depression scores for the HADS were 4.9 and 2.8, respectively, which were not higher than previously reported general population norms [43]. The means across different genetic risk groups also did not differ significantly (Table 2; anxiety: $P = 0.99$; depression: $P = 0.75$).

None of the independent variables showed a significant association with either the anxiety or depression scores. Those with higher risk perception had slightly higher scores on the anxiety and depression scales ($P = 0.02$ and $P = 0.03$, respectively; Table 3), although the difference was not clinically significant.

IES, CWS, MAX-PC Questionnaires

At the univariate level, the mean intrusion and avoidance scores on the IES scale were significantly higher in both *BRCA1* and *BRCA2* mutation carriers compared with controls (intrusion: $P = 0.001$; avoidance: $P < 0.001$; Table 2) and higher in those who perceived their PCa risk as moderately or strongly increased (intrusion: $P < 0.001$, avoidance: $P = 0.001$; Table 3); however, at the multivariate level, risk perception contributed more significantly to the variation in IES scores than genetic status (Table 4).

A similar pattern was seen for the cancer worry score. Scores were generally low and univariately associated with genetic status (CWS-R: $P = 0.004$; Table 2) and risk perception (CWS: $P < 0.001$; Table 3). Again, risk perception was more

Table 1 Sociodemographic characteristics of the cohort.

	<i>n</i>	%
Education	415	96.1
Pre-high school	108	25.0
High school or technical	144	33.3
Degree or postgraduate	163	37.7
Employment	429	99.3
In active paid work	328	75.9
Retired	82	19.0
Unemployed	19	4.4
Family history of prostate cancer	432	100
None	293	67.8
In ≥ 1 first degree relative	139	32.2
Time since genetic testing	424	98.1
0–3 months prior to enrolment	125	28.9
3–6 months	76	17.6
6–12 months	48	11.1
12–24 months	49	11.3
2–5 years	76	17.6
>5 years	50	11.6
Age	Mean: 53.1; Median: 53.0	SD: 8.5

Table 2 Descriptive statistics and summary of group comparisons for the psychosocial variables.

Scale	Scale range / threshold		Overall		BRCA1 mutation carriers		BRCA2 mutation carriers		Controls		Cohen's <i>d</i> *
			N	Mean (sd) % above threshold	N	Mean (sd) % above threshold	N	Mean (sd) % above threshold	N	Mean (sd) % above threshold	
SF-36 physical component summary	Range	0–100	404	47.4 (10.0)	90	46.4 (10.7)	148	47.1 (10.1)	166	48.3 (8.6)	
SF-36 mental component summary	Range	0–100	404	52.4 (10.2)	90	52.1 (11.1)	148	51.2 (10.5)	166	53.7 (9.3)	
Total anxiety (HADS)	Range	0–21	431	4.9 (3.6)	97	4.9 (3.5)	160	4.8 (3.8)	174	4.9 (3.4)	
	Abnormal threshold	≥11	28	6.5%	6	6.2%	12	7.5%	10	5.7%	
Total depression (HADS)	Range	0–21	431	2.8 (3.0)	97	2.9 (3.2)	160	2.9 (3.1)	174	2.7 (2.7)	
	Abnormal threshold	≥11	9	2.1%	3	3.1%	4	2.5%	2	1.1%	
Total intrusion (IES)	Range	0–35	423	2.3 (4.9)	94	3.0[†] (5.7)	158	3.1[†] (5.5)	171	1.3[†] (3.5)	–0.02; 0.35; 0.38
	Abnormal threshold	≥19	12	2.8%	4	4.3%	6	3.8%	2	1.2%	
Total avoidance (IES)	Range	0–40	418	4.3 (7.0)	93	6.0[†] (8.4)	156	5.1[†] (7.4)	169	2.6[†] (5.2)	0.11; 0.48; 0.39
	Abnormal threshold	≥19	32	7.7%	12	12.9%	15	9.6%	5	3.0%	
Total MAX-PC	Range	0–33	420	3.5 (5.4)	94	4.1 (5.5)	156	3.9 (6.2)	170	2.8 (4.6)	
Total cancer worry	Range	4–24	430	9.5 (2.5)	97	9.7[†] (2.7)	160	9.9[†] (2.7)	173	9.1[†] (2.0)	–0.09; 0.25; 0.36
	Risk perception		423	N/A	91	N/A	156	N/A	171	N/A	
	Moderately or strongly increased		133	31.4%	31	32.3%[‡]	86	55.1%[‡]	16	9.4%[‡]	0.43 [§]
Total knowledge score	Range	0–9	404	7.1 (1.7)	92	6.9 (1.8)	151	7.2 (1.6)	161	7.1 (1.7)	

HADS, Hospital Anxiety and Depression Scale; IES, Impact of Event Scale; MAX-PC, Memorial Anxiety Scale for Prostate Cancer; SF-36, 36-item short-form health survey.

*Cohen's *d* values are listed comparing BRCA1 mutation carriers with BRCA2 mutation carriers; BRCA1 mutation carriers with controls; BRCA2 mutation carriers with controls.

[†]*P* < 0.01 using ANOVA. [‡]*P* < 0.01 using a chi-squared test for independence. [§]Cramer's *V* test for nominal association. Bold font indicates statistically significant values.

Table 3 Means of psychosocial scales according to risk perception categories.

Scale (mean scores)	Risk perception		<i>P</i>	Cohen's <i>d</i>
	Not or slightly increased	Moderately/strongly increased		
HADS anxiety	4.54	5.43	0.02	
HADS depression	2.55	3.23	0.03	
IES intrusion	1.33	4.42	<0.001	–0.57
IES avoidance	3.32	6.11	0.001	–0.39
MAX-PC (PCa)	2.62	5.32	<0.001	–0.47
CWS-R	8.89	10.84	<0.001	–0.76

CWS-R, Cancer Worry Scale-Revised; HADS, Hospital Anxiety and Depression Scale; IES, Impact of Event Scale; MAX-PC, Memorial Anxiety Scale for Prostate Cancer; PCa, prostate cancer; SF-36, 36-item short-form health survey.

highly associated with higher cancer worry than genetic status in the multivariate model (Table 4).

Scores for PCa anxiety (MAX-PC) were only associated with risk perception (*P* < 0.001), therefore, a multivariate analysis was not undertaken.

Discussion

This study investigated the baseline HRQoL and psychosocial profiles of men taking part in the IMPACT study, prior to their first screening appointment. The results indicate that participants, in general, do not have clinically concerning levels of general or cancer-specific distress (i.e. indicative of the presence of clinical depression or anxiety) or poor HRQoL. A small subset of participants had higher levels of distress, but perception of risk contributed more to explaining the variance in distress level than did genetic status. General population screening studies in the UK and European series have reported similar findings: that PCa screening does not have a detrimental effect on measures of HRQoL and psychological health [28,44,45].

It was reassuring that participants' perceptions of PCa risk were influenced by carrier status, largely reflecting what would have been communicated during genetic counselling [2,3]. As expected, BRCA2 mutation carriers had the highest perceived risk of PCa, most frequently classifying risk as

Table 4 Results of multivariable linear regression analysis for the Hospital Anxiety and Depression Scale, Impact of Events Intrusion and Avoidance, and Cancer Worry Scale-Revised.

Variables		B	SE	T	P	R ²	R ² change
IES intrusion	Risk perception	2.92	0.55	5.32	<0.001	0.087	0.087
	BRCA2 status	0.42	0.58	0.72	0.47	0.087	0.000
	BRCA1 status	0.98	0.62	1.59	0.11	0.092	0.006
IES avoidance	Risk perception	2.18	0.81	2.70	0.007	0.058	0.017
	BRCA2 status	1.50	0.85	1.76	0.08	0.042	0.025
	BRCA1 status	2.88	0.91	3.18	0.002	0.017	0.017
CWS-R	Risk perception	1.98	0.27	7.46	<0.001	0.137	0.137
	BRCA2 status	-0.07	0.28	-0.24	0.81	0.138	0.001
	BRCA1 status	0.14	0.30	0.47	0.64	0.138	0.000

CWS-R, Cancer Worry Scale-Revised; HADS, Hospital Anxiety and Depression Scale; IES, Impact of Event Scale. Variables included represent those significant on the univariate level.

‘slightly’ or ‘moderately’ increased, and controls most frequently classifying risk as the ‘same’ as the general population.

Knowledge levels were high across the cohorts, irrespective of genetic status, education level and time since testing, showing that men retained accurate information about inheritance of *BRCA1/BRCA2* mutations and cancer risk. The knowledge questionnaire was designed specifically for this study, but was adapted from that used in other studies [37,38]. These studies reported knowledge levels to be ~50% in women at risk of breast cancer prior to *BRCA1/BRCA2* testing. The high levels of knowledge reported in our cohort could reflect that they have recently revisited their risk status in making a decision to undergo screening in the IMPACT study; however, men were asked to complete these questionnaires prior to their first screening appointment and so may not have had a detailed discussion about risk of PCa since being informed about their genetic status.

The sociodemographic characteristics of the cohort indicate that employment and education levels are similar to those observed in the UK general population [41,42]; however, participants were predominantly white, which is not representative of the general UK population, and therefore caution should be exercised in generalizing these results to other ethnic groups.

The HRQoL assessments did not detect any clinically relevant differences in either physical or mental health when compared with general population samples, both matched and unmatched by age [34]. Our results support those of the Finnish European Randomized Screening for Prostate Cancer study cohort in which HRQoL was also assessed with the SF-36 [45]. As in our cohort, HRQoL scores were observed to be higher than in the general Finnish population [45], but not at clinically significant levels; this was hypothesized to be because the men were generally healthy and well educated; however the Finnish cohort was not age-matched, which may have conferred some bias.

In terms of general distress, scores were within previously reported population norms [43] and no differences were observed between mutation carriers and controls. For cancer-specific distress, a significant difference was found between *BRCA* mutation carriers and controls for both the IES and CWS; however the differences were small and mean scores remained below clinically relevant levels for the IES. Importantly, at the multivariate level, risk perception was found to have a stronger association with distress levels than genetic status itself.

No significant association was observed between anxiety and having a family history of PCa, supporting previous reports [15,24,28,44,46]. Men reporting higher PCa risk perception were found to have consistently higher scores across all psychological distress scales (general and cancer-specific). Similar results were reported by Taylor et al. [24]; however, the effect size was small across all scales and no group had a mean distress score that reached clinically significant levels, where such thresholds were available [30,43]. It is therefore fair to conclude that, whilst having a modest impact on men’s distress levels, a high perceived PCa risk is not associated strongly with clinically significant levels of distress in this cohort.

A number of studies have reported that anxiety about cancer screening affects a small number of people who are predisposed to anxiety, and that this anxiety continues throughout participation in cancer screening [16,27,28,44,47]. Our data support this finding, with a small proportion of men reporting clinically significant levels of distress. It will be important to compare these baseline levels with subsequent screening rounds in the IMPACT study and to include previous high PSA results as a covariate, as both the European and US screening studies report high levels of anxiety in men with previously elevated PSA levels [26,27]. Identifying men with a predisposition to high levels of psychological distress could facilitate providing timely support to manage this distress and potentially increase adherence to screening recommendations.

We did not observe a significant association between distress and age. While this supports several earlier studies [16,44], one study reported an inverse relationship between age and distress levels [27].

It is important to consider whether we would have observed different results if all men in the IMPACT study had been included in this psychosocial sub-study; however we found no difference in sociodemographic characteristics between the men in the sub-study and those in the IMPACT study as a whole. It could be that those more predisposed to anxiety may be inclined not to join the psychosocial sub-study; however, no evidence of this has been found by others [28].

We obtained a very high uptake level for the psychosocial sub-study, with at least 85% opting in at participating sites. Uptake was also found to be high in the European Randomized study of Screening for Prostate Cancer Swedish cohort, with 84–94% of men with abnormal PSA levels completing a questionnaire measuring anxiety levels [27]. The high participation rate is probably attributable to the embedding of this psychosocial study into an existing screening study, and therefore inviting participants who are already highly motivated to contribute to research.

A strength of the present study is the use of a number of different, standardized psychological measures that offer extensive insight into the psychosocial profile of the participants and that allow comparison of the results with a number of other PCa screening studies that have used the same or similar measures.

It should be noted that our sample was restricted to men who have previously engaged with health services by undergoing genetic testing and who responded positively to an invitation to take part in a research study. In addition, there was limited variability in ethnicity, which may limit the generalizability of the findings to other populations.

The data presented represent a snapshot of men's psychosocial profiles when they joined the IMPACT study. Follow-up data will inform whether the PCa screening process has an impact on HRQoL or distress over time.

To the best of our knowledge, this is the first study to report the psychosocial and HRQoL profile of men with *BRCA1/BRCA2* mutations taking part in a PCa screening study. Uptake into the study was very high, and participants had very high levels of knowledge about genetics and PCa. As a whole, the cohort did not demonstrate any clinically concerning levels of general or cancer-specific distress or poor HRQoL. A small subset of participants reported higher levels of distress, but perception of risk was more strongly associated with distress levels than was genetic status. It is important for healthcare professionals who are providing PCa screening

to be aware of these predictors of distress so that men with potential for heightened distress can be identified and adequate counselling and support can be offered. Follow-up data will determine whether these factors have an impact on adherence to screening and whether men experiencing abnormal PSA results experience more distress.

Acknowledgements

This research was coordinated by the Institute of Cancer Research, London, UK and is supported by grants from Cancer Research UK (Grant references (C5047/A21332, C5047/A13232 and C5047/A17528) and the Ronald and Rita McAulay Foundation. We acknowledge support from the National Institute for Health Research (NIHR) to the Biomedical Research Centres at The Institute of Cancer Research and Royal Marsden Foundation NHS Trust, at Central Manchester Foundation Trust and the Oxford Biomedical Research Centre Programme. The Institute of Cancer Research is the Sponsor of the IMPACT study. We thank Mr and Mrs Jack Baker for support for the study in NorthShore University HealthSystem, Evanston, IL, USA.

Conflict of Interest

Prof. Rosalind Eeles: Janssen Pharmaceutica, provided medical education support to GU ASCO February 2013, and received an honorarium and expenses for attending and speaking at the UK Cancer Convention, October 2013 from Succinct Communications. The remaining authors have no other conflict of interest to declare.

References

- 1 Globocan Cancer Fact Sheets. Available at: <http://globocan.iarc.fr/old/FactSheets/cancers/prostate-new.asp>. Accessed January 2018
- 2 Leongamornlert D, Mahmud N, Tymrakiewicz M et al. Germline *BRCA1* mutations increase prostate cancer risk. *Br J Cancer* 2012; 106: 1697–701
- 3 Kote-Jarai Z, Leongamornlert D, Saunders E et al. *BRCA2* is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. *Br J Cancer* 2011; 105: 1230–4
- 4 Castro E, Goh C, Olmos D et al. Germline *BRCA* mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. *J Clin Oncol* 2013; 31: 1748–57
- 5 Gallagher DJ, Gaudet MM, Pal P et al. Germline *BRCA* mutations denote a clinicopathologic subset of prostate cancer. *Clin Cancer Res* 2010; 16: 2115–21
- 6 Bancroft EK, Page EC, Castro E et al. Targeted prostate cancer screening in *BRCA1* and *BRCA2* mutation carriers: results from the initial screening round of the IMPACT study. *Eur Urol* 2014; 66: 489–99
- 7 Catalona WJ. Prostate cancer screening. *Med Clin North Am* 2018; 102: 199–214
- 8 U.S. Preventive Services Taskforce. Available at: <https://screeningforprostatecancer.org/>. Accessed April 2018
- 9 Catalona WJ, Antenor JA, Roehl KA, Moul JW. Screening for prostate cancer in high risk populations. *J Urol* 2002; 168: 1980–3
- 10 Kiemeny LA, Broeders MJ, Pelger M et al. Screening for prostate cancer in Dutch hereditary prostate cancer families. *Int J Cancer* 2008; 122: 871–6

- 11 Makinen T, Tammela TL, Stenman UH et al. Family history and prostate cancer screening with prostate-specific antigen. *J Clin Oncol* 2002; 20: 2658–63
- 12 Uzzo RG, Pinover WH, Horwitz EM et al. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digital rectal examination. *Urology* 2003; 61: 754–9
- 13 Foster C, Watson M, Eeles R et al. Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up. *Br J Cancer* 2007; 96: 718–24
- 14 Meiser B. Psychological impact of genetic testing for cancer susceptibility: an update of the literature. *Psycho-Oncology* 2005; 14: 1060–74
- 15 Sweetman J, Watson M, Norman A et al. Feasibility of familial PSA screening: psychosocial issues and screening adherence. *Br J Cancer* 2006; 94: 507–12
- 16 Brindle LA, Oliver SE, Dedman D et al. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK. *BJUI Int* 2006; 98: 777–82
- 17 Bancroft EK, Castro E, Bancroft G et al. The psychological impact of undergoing genetic-risk profiling in men with a family history of prostate cancer. *Psycho-Oncology* 2015; 24: 1492–9
- 18 Bratt O, Damber JE, Emanuelsson M et al. Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer. *Eur J Cancer* 2000; 36: 235–41
- 19 Cormier L, Guillemin F, Valeri A et al. Impact of prostate cancer screening on health related quality of life in at-risk families. *Urology* 2001; 59: 901–6
- 20 Strømsvik N, Raheim M, Gjengedal E. Cancer worry among Norwegian male BRCA 1/2 mutation carriers. *Fam Cancer* 2011; 10: 597–603
- 21 Hallowell N, Arden-Jones A, Eeles R et al. Communication about genetic testing in families of male BRCA1/2 carriers and non-carriers: patterns, priorities and problems. *Clin Genet* 2005; 67: 492–502
- 22 Hallowell N, Arden-Jones A, Eeles R et al. Guilt, blame and responsibility: men's understanding of their role in the transmission of BRCA1/2 mutations within their family. *Sociol Health Illn* 2006; 28: 969–88
- 23 Moynihan C, Bancroft EK, Mitra A et al. Ambiguity in a masculine world: being a BRCA1/2 mutation carrier and a man with prostate cancer. *Psychooncology* 2017; 26: 1987–93
- 24 Taylor KL, Di Placido J, Redd WH, Faccenda K, Greer L, Perlmutter A. Demographics, family histories, and psychological characteristics of prostate carcinoma screening participants. *Cancer* 1999; 85: 1305–12
- 25 Taylor KL, Shelby R, Kerner J, Redd W, Lynch J. Impact of undergoing prostate carcinoma screening on prostate carcinoma-related knowledge and distress. *Cancer* 2002; 95: 1037–44
- 26 Taylor KL, Shelby R, Gelmann E, McGuire C. Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. *J Natl Cancer Inst* 2004; 96: 1083–94
- 27 Carlsson S, Aus G, Wessman C, Hugosson J. Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) – results from a prospective, population-based, randomised study. *Eur J Cancer* 2007; 43: 2109–16
- 28 Essink-Bot ML, de Koning HJ, Nijs HGT, Kirkels WJ, van der Maas PJ, Schroder FH. Short-term effects of population-based screening for prostate cancer on health-related quality of life. *J Natl Cancer Inst* 1998; 90: 925–31
- 29 Zigmund AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983; 67: 361–70
- 30 Horowitz M. Stress response syndromes and their treatment. In Goldberger L, Breznitz S eds, *Handbook of Stress: Theoretical and Clinical Aspects*. New York, NY: Free Press, 1982: 711–32.
- 31 Lerman C, Trock B, Rimer BK, Boyce A, Jepson C, Engstrom PF. Psychological and behavioural implications of abnormal mammograms. *Ann Intern Med* 1991; 114: 657–61
- 32 Watson M, Lloyd S, Davidson J et al. The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer. *Br J Cancer* 1999; 79: 868–74
- 33 Dale W, Hemmerich J, Meltzer D. Extending the validity of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) at the time of prostate biopsy in a racially-mixed population. *Psycho-Oncology* 2007; 16: 493–8
- 34 Jenkinson C, Stewart-Brown S, Petersen S, Paice C. Assessment of the SF-36 version 2 in the United Kingdom. *J Epidemiol Community Health* 1999; 53: 46–50
- 35 Ware J, Sherbourne C. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992; 30: 473
- 36 Lerman C, Lustbader E, Rimer B et al. Effects of individualized breast cancer risk counseling: a randomized trial. *J Natl Cancer Inst* 1995; 87: 286–92
- 37 Lerman C, Narod S, Schulman K. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. *JAMA* 1996; 275: 1885–92
- 38 Wonderlick AL, Fine BA. Knowledge of breast cancer genetics among breast cancer patients and first-degree relatives of affected individuals. *J Gen Couns* 1997; 6: 111–30
- 39 Maruish ME, DeRosa MA. *A Guide to the Integration of Certified Short Form Survey Scoring and Data Quality Evaluation Capabilities*. Lincoln, RI: QualityMetric Incorporated, 2009.
- 40 Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. *J Clin Epidemiol* 1994; 47: 1245–51
- 41 Office for National Statistics. Available at: <https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentandemployeetypes/timeseries/lf24>. Accessed April 2018
- 42 Office for National Statistics. Available at: <https://data.oecd.org/eduatt/population-with-tertiary-education.htm>. Accessed April 2018
- 43 Breeman S, Cotton S, Fielding S, Jones GT. Normative data for the hospital anxiety and depression scale. *Qual Life Res* 2015; 24: 391–8
- 44 Macefield RC, Lane JA, Metcalfe C et al. Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy? *Eur J Cancer* 2009; 45: 2569–73
- 45 Vasarainen H, Malmi H, Määttänen L et al. Effects of prostate cancer screening on health-related quality of life: results of the Finnish arm of the European randomized screening trial (ERSPC). *Acta Oncol* 2013; 52: 1615–21
- 46 Bratt O, Emanuelsson M, Grönberg H. Psychological aspects of screening in families with hereditary prostate cancer. *Scand J Urol Nephrol* 2003; 37: 5–9
- 47 Brunton M, Jordan C, Campbell I. Anxiety before, during, and after participation in a population-based screening mammography programme in Waikato Province, New Zealand. *N Z Med J* 2005; 118: U1299

Correspondence: Elizabeth K. Bancroft, Institute of Cancer Research, 123 Old Brompton Rd, London SW7 3RP, UK.

e-mail: elizabeth.bancroft@rmh.nhs.uk

Abbreviations: CWS-R, Cancer Worry Scale-Revised; HADS, Hospital Anxiety and Depression Scale; HRQoL, health-related quality of life; IES, Impact of Event Scale; MAX-PC, Memorial Anxiety Scale for Prostate Cancer; PCa, prostate cancer; SF-36, 36-item short-form health survey.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Appendix S1. The IMPACT Collaborators.